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 ABSTRACT
While haemolytic uraemic syndrome in children is 
predominantly associated with Shiga toxin -producing 
Escherichia coli (typically 0157:H7), some cases 
occur without associated diarrhoea, or as the mani-
festation of an underlying disorder other than infec-
tion. Haemolytic uraemic syndrome is characterised 
by microangiopathic anaemia, thrombocytopaenia 
and renal failure, on occasion accompanied by severe 
hypertension. Malignant hypertension is a syndrome 
that sometimes exhibits the same laboratory abnor-
malities as haemolytic uraemic syndrome as it may 
share the same pathological findings: thrombotic 
microangiopathy. As clinical features of both entities 
overlap, the distinction between them can be very 
difficult. However, differentiation is essential for the 
treatment decision, since early plasma exchange 
dramatically reduces mortality in haemolytic uraemic 
syndrome not associated with diarrhoea. An increas-
ing number of genetic causes of this pathology have 
been described and may be very useful in differen-
tiating it from thrombotic microangiopathy due to 
other aetiologies. Despite advances in the under-
standing of the pathophysiology of haemolytic ura-
emic syndrome not associated with diarrhoea, the 
management often remains empirical. We describe 
a patient with simultaneous microangiopathic hae-
molytic anaemia, thrombocytopaenia and severe 
hypertension managed in the acute period of illness 
with plasma exchange.
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 INTRODUCTION
Thrombotic microangiopathy (TMA) is a pathologi-
cal finding characterised by arteriolar fibrinoid necro-
sis, intimal thickening and media proliferation with 
resultant luminal narrowing leading to excess frag-
mentation of erythrocytes and consumption of 
platelets1 -3. Laboratory findings of TMA include 
microangiopathic haemolytic anaemia and thrombo-
cytopaenia and elevation of serum lactacte 
dehydrogenase1,4 -6. TMA, while typically associated 
with Haemolytic Uraemic Syndrome (HUS), can how-
ever occur in association with other conditions, includ-
ing malignant hypertension, sepsis, Systemic Lupus 
Erythematosus, systemic sclerosis and malignant 
disease1,7 -9. HUS is the consensual term for children 
who meet the diagnostic criteria of thrombocytopaenia 
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and microangiopathic haemolytic anaemia along with 
renal failure. Thrombocytopaenic thrombotic purpura 
(TTP) is reserved for the rare children who present 
with these laboratory findings but without renal fail-
ure or for patients with congenital deficiency of 
ADAMTS13 (“a desintegrin-like and metalloprotease 
with thrombospondin type I repeats”) activity6. These 
definitions and syndrome classification are still the 
subject of debate. Typical HUS is the main cause of 
renal impairment in young children and is caused by 
verocytotoxin (shiga-like toxin)-producing bacteria, 
usually by enterohaemorrhagic Escherichia coli sero-
type O157:H7 and is associated with prodromal diar-
rhoea (it is also known as typical HUS, diarrhoea 
associated HUS or D+HUS) although other serotypes 
and even other bacteria may be responsible for this 
entity7. Supportive therapy and control of infection 
are prescribed in these cases. All remaining HUS 
cases, commonly referred to as atypical HUS, imply 
a thorough investigation which will reveal a risk fac-
tor in more than half the cases (Table I)9. Disorders 
of complement regulation account for the majority of 
cases but other genetic or acquired abnormalities 
may present initially as TTP-HUS, such as deficiency 
of the enzyme ADAMTS13, a specific protease that 
cleaves multimeric von Willebrand protein and may 
be decisive in therapeutic management3,4,6-9. Plasma 
exchange substantially reduces the mortality in these 
situations from 90% to 10%4,6. The authors report 
the case of a patient with microangiopathic haemo-
lytic anaemia, thrombocytopaenia and renal impair-
ment associated with severe hypertension, which 
made the differential diagnosis and therapeutic 
approach difficult.
 CASE REPORT
A healthy five -year -old Indian boy, resident in 
Portugal for three years, began to have complaints 
of morning vomiting lasting for one to three days, 
sometimes accompanied by frontal headache, 
which prompted several health centre visits about 
three months before hospital admission. In the 
week before admission he was evaluated in the 
emergency room for vomiting and facial palsy. His 
brain CAT scan showed bilateral lenticular hypoden-
sities and he was symptomatically medicated with 
paracetamol and ibuprofen and referred for a Neu-
rology consultation. One week later he was admit-
ted with incoercible vomiting. He had no fever, 
diarrhoea or other complaints. At the time of 
admission the physical examination revealed a very 
ill boy with right facial palsy, pallor, jaundiced 
sclerotic, cardiac systolic murmur II / VI, normal 
lung auscultation, painless abdomen with no orga-
nomegaly or murmurs, no signs of haemorrhagic 
discrasy, dehydration, fever or respiratory distress. 
His BP was 238/134mmHg. Laboratory investigation 
revealed haemoglobin 13.6g/dl and a platelet count 
of 109,000/l, reticulocyte count 2.95%, mild renal 
insufficiency (GFR 61ml/1.73m2/min), mild unconju-
gated hyperbilirubinaemia (total bilirubin/direct 
bilirubin 1.48/0.58 mg/dl) and serum lactate dehy-
drogenase 1011mg/dl. Spherocytes and schistocytes 
were found in a peripheral blood smear. Large 
amounts of haemoglobin, proteins and glucose 
were present in his urine. There were no changes 
in coagulation and liver tests. The blood and urine 
cultures performed were all negative. Abdominal 
ultrasound was normal and renal ultrasound 
showed absence of renal parenchymal-sinus dif-
ferentiation. Chest X-ray showed a nonspecific 
bilateral interstitial infiltrate and a slightly increased 
cardiothoracic index. Brain angiography MR showed 
“multifocal lesions involving mainly the nuclei of 
the grey base and the bulb, with no obvious signs 
of brain arteritis or acute/subacute ischaemia or 
Table I
Classification of HUS, TTP, and related disorders3
1. Aetiology advanced
 1.1. Infection induced
  1.1.1.  Shiga and shiga-like toxin-producing bacteria: Enterohaemor-
rhagic Escherichia coli, Shigella dysenteriae type 1, Citrobacter 
freundii
  1.1.2. Streptococcus pneumoniae
 1.2. Disorders of complement regulation
  1.2.1. Genetic
  1.2.2. Acquired
 1.3. Defective cobalamin metabolism
 1.4. Quinine induced
2. Clinical associations: aetiology unknown
 2.1. HIV infection
 2.2. Malignancy, cancer chemotherapy, ionising radiation
 2.3. Calcineurin inhibitors and transplantation
 2.4. Pregnancy HELLP syndrome, contraceptive pill
 2.5.  Systemic lupus erythematosus, anti -phospholipid antibody syn-
drome, systemic sclerosis
 2.6. Glomerulopathy
 2.7. Familial not included in level 1
 2.8. Unclassified
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bleeding”. The EEG, cardiology and ophthalmology 
evaluations were normal. The immunology param-
eters (C3, C4, CH100, antinuclear antibody ANA, anti 
double stranded DNA antibody anti-dsDNA, circulat-
ing immunocomplexes CIC, anti-extractable nuclear 
antigen anti-ENA, lupus anticoagulant LA, anti-car-
diolipin antibody ACL and antiphospholipidic anti-
body) were all negative. The functional study of 
the thyroid and suprarenal glands (active renin, 
aldosterone, serum and urinary catecholamines, 
metanephrin and nor-metanephrin and vanilman-
delic acid) showed no changes. Serologies for HIV 
and Hepatitis B virus were negative. ADAMTS13 
activity was 89% (normal range (NR) 40-130%), the 
ADAMTS13 antigen was 57% (NR 70-160%) and the 
anti-ADAMTS13 antibody was 1U/ml (NR <15 U / ml). 
Definitive results from serum and genetic analysis 
of complement regulatory factors H, I, MCP or 
CD46 were not available as the first blood samples 
had technical issues that made laboratory investi-
gation impossible and, in the meantime, the child 
returned to India. Treatment with infusion of labe-
talol (0.5 mg/kg/h to 2mg/kg/h) and nifedipine for 
24 hours followed by oral antihypertensive therapy 
with nifedipine (0.9 to 1.8 mg/kg/day) and enalapril 
(0.2 to 0.5 mg/kg/day), resulted in significant improve-
ment of blood pressure with normalisation in the 
second week of admission. As he remained symp-
tomatic (vomiting, abdominal pain, prostration and 
headache) along with a rapidly progressive worsen-
ing of the intravascular haemolysis and renal failure 
(Hb 11.4g/dl, Htc 30.2%, reticulocytes 4.95%, hap-
toglobin <0.08g/l, platelets 105,000/μl, GFR 41.9ml/
mn/1.73m2), plasma exchange was initiated (1 vol-
ume per session) and three cycles were performed. 
There was a remarkable clinical and biochemical 
improvement after the start of plasma exchange, 
with a remaining complaint of sporadic abdominal 
pain only that disappeared on the third day of 
treatment. Table II shows laboratory findings and 
therapeutic approach during the first week of hos-
pital stay. Diuresis and weight remained normal 
during his hospital stay and there was a single 
episode of high temperature (38ºC) during the last 
plasma exchange session, with negative blood 
cultures. The renal ultrasound repeated on the 15th 
day of admission showed the same changes as on 
admission. He was discharged on the 21st day of 
admission, clinically well, with persistence of his 
facial palsy and normal BP under oral treatment 
with enalapril and nifedipine. A renal biopsy was 
performed 65 days after the acute episode and 
showed a morphological pattern of interstitial 
fibrosis with inflammatory infiltrate of mononu-
cleated cells around atrophic tubules in more than 
half of the cortex as well as arteriolar media hyper-
trophy and intimae fibrocellular thickening with 
marked reduction or total occlusion of the lumen 
and arterial media hypertrophy. As of the fifth 
month of hospital discharge, he remains clinically 
well with only a slight/moderate facial palsy and 
blood pressure around 100/57mmHg.
Table II
Clinical and laboratory evolution and therapeutic approach during the first week of hospital stay
Day of hospital stay 1st 3rd 4th 5th









GFR: 41.9 mL/mn/1.73m2 
Haptoglobin <0.08g/L







Blood smear: Rare sphero-






Blood smear: Rare sphero-
cytes and schistocytes 
Mean blood pressure 220/135 mmHg 131/64 mmHg 142/75 mmHg 147/92 mmHg
Treatment Infusion of labetalol (0.5 mg/
kg/h to 2mg/kg/h) and nife-
dipine followed by oral ther-
apy with nifedipine (0.9 to 
1.8 mg / kg/day) and enal-
april (0.2 to 0.5 mg/kg/day)
Plasmapheresis
Oral nifedipine 
(0.9 to 1.8 mg/kg /day)
Oral enalapril 
(0.2 to 0.5 mg/kg/day)
Plasmapheresis
Oral nifedipine 
(0.9 to 1.8 mg/kg/day)
Oral enalapril 
(0.2 to 0.5 mg/kg/day)
Plasmapheresis
Oral nifedipine 
(0.9 to 1.8 mg/kg/day)
Oral enalapril 
(0.2 to 0.5 mg/kg/day)
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 DISCUSSION
After sudden onset of intravascular haemolysis 
and thrombocytopaenia along with severe hyperten-
sion, renal and neurological compromise, with no 
reference to diarrhoea, drugs or toxic ingestion and 
a negative infectious and immunologic investigation, 
the differential diagnosis focused mainly between 
D- HUS and malignant hypertension7,9. The dia-
stolic values higher than 130 mmHg and the only 
mild thrombocytopaenia favoured the diagnosis of 
malignant hypertension, but this hypothesis seemed 
less likely, given the absence of previous hyperten-
sion and the lack of impact on the usual target 
organs (normal ophthalmology and cardiology 
examinations)2. According to the literature, the first-
line treatment for HUS not linked to diarrhoea is 
plasma exchange which significantly reduces mortal-
ity (from 90% to 10 -30%) when promptly 
instituted1 -3,7,10,11. This evidence explains the 
decreased stringency of criteria for the diagnosis of 
HUS and thrombocytopaenia and microangiopathic 
haemolytic anaemia without identifiable cause are 
sufficient for making this diagnosis and starting 
plasma exchange3,7,9. Sometimes, as with this child, 
anaemia is not immediately apparent but this should 
not delay the institution of therapy, if other labora-
tory signs of haemolysis are present, such as the 
evidence of erythrocyte fragmentation3. In the con-
text of microangiopathic anaemia with thrombocy-
topaenia along with severe hypertension, some 
authors suggest that plasma exchange should be 
performed in all patients with moderate to severe 
forms of thrombocytopaenia accompanying microan-
giopathic anaemia (platelets 20,000-50,000/μl)2 as 
most of the reported cases of thrombocytopaenia 
due to malignant hypertension have platelet counts 
of more than 50,000/μl12,13, although there are some 
exceptions14,15. Nonetheless, recent articles show 
that TMA may be present with substantial renal 
injury in the presence of normal values of platelets10. 
More studies to determine the usefulness of plasma 
exchange in these atypical athrombocytopaenic 
forms of TMA are necessary. As serum analysis of 
ADAMTS13 and von Willebrand multimers was not 
ready and as there was laboratory worsening of the 
microangiopathy and renal failure despite aggressive 
arterial pressure control, we felt the need for medi-
cal intervention other than blood pressure control 
and started daily sessions of plasma exchange with 
fresh frozen plasma (one plasma volume)3,11. Clinical 
and biochemical improvement following the institu-
tion of plasma exchange does not, however, rule out 
malignant hypertension since antihypertensive ther-
apy was given simultaneously and blood pressure 
control seems to be sufficient for the remission of 
the clinical picture observed in malignant hyperten-
sion2. However, by this time, the hypertension was 
not totally controlled (BP>P95). A normal ADAMTS13 
result of does not allow confirmation of diagnosis 
and obviate the determination of von Willebrand 
factor multimers which are cleaved by this pro-
tease10. Neither the changes in the brain MR nor 
angiography MR were specific to any of the diagno-
ses in question. Indeed, the histological examination 
of the biopsy was frankly suggestive of TMA but the 
morphological findings were not specific of either of 
the two clinical entities. Serum and genetic analysis 
of complement factors would be very useful for a 
possible confirmation of the diagnosis of D- HUS 
and ensuing treatment of the patient3,7.
 CONCLUSION
As described in this patient, microangiopathic 
haemolysis accompanied by severe hypertension 
makes a timely diagnosis extremely difficult to 
establish. The evidence of reduced mortality in 
patients with D - HUS treated promptly with plasma 
exchange and the laboratory worsening in our child 
despite mild thrombocytopaenia and aggressive 
blood pressure control seemed to justify our thera-
peutic decision. Moreover, any delay in performing 
plasma exchange may reduce its efficacy. The 
reduced activity of ADAMTS13 as well as abnor-
malities in complement regulation is useful in the 
differential diagnosis but the results were not ready 
for a timely decision. The absence of such changes 
does not rule out the diagnosis, since other patho-
genic mechanisms are described and many cases of 
D - HUS are idiopathic.
The diagnosis of D - HUS is often presumptive, 
which makes the decision to initiate plasma 
exchange very difficult. There are currently no data 
demonstrating the effectiveness of any therapeutic 
modality beyond plasma exchange. Future research 
should address these aspects3.
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